Sorafenib, a multi‐kinase inhibitor, is the only standard clinical drug for patients with
advanced hepatocellular carcinoma (HCC); however, development of sorafenib resistance …

Purpose: Sorafenib, an oral multikinase inhibitor, is the first agent that has demonstrated an
improved overall survival benefit in advanced hepatocellular carcinoma, setting a new …

Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Sorafenib is effective for patients with advanced hepatocellular carcinoma (HCC) and
particularly for those who are unsuitable to receive life-prolonging transarterial …

Patients with unresectable hepatocellular carcinoma (HCC) usually have poor prognosis
because current monotherapy including surgery, chemotherapy and radiotherapy (RT) are …

AIM: To investigate the inhibitory role and the underlying mechanisms of sorafenib on signal
transducer and activator of transcription 3 (STAT3) activity in hepatocellular carcinoma …

Trichostatin A (TSA), a hydroxamate histone deacetylase inhibitor, is a compound that has
been identified to induce anticancer activity. The aim of the present study was to investigate …

Background: Deregulated RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways are
found in hepatocellular carcinoma (HCC). This study aimed to test the inhibitory effects of PI …

Background Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-
associated mortality worldwide. Sorafenib (SORA), as a first-line therapeutic drug, has been …